261 related articles for article (PubMed ID: 17967943)
1. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.
Kim HG; Kojima K; Swindle CS; Cotta CV; Huo Y; Reddy V; Klug CA
Blood; 2008 Feb; 111(3):1567-74. PubMed ID: 17967943
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
3. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
4. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
5. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
[TBL] [Abstract][Full Text] [Related]
7. Cbfbeta reduces Cbfbeta-SMMHC-associated acute myeloid leukemia in mice.
Heilman SA; Kuo YH; Goudswaard CS; Valk PJ; Castilla LH
Cancer Res; 2006 Dec; 66(23):11214-8. PubMed ID: 17145866
[TBL] [Abstract][Full Text] [Related]
8. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
9. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
10. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16).
Markus J; Garin MT; Bies J; Galili N; Raza A; Thirman MJ; Le Beau MM; Rowley JD; Liu PP; Wolff L
Cancer Res; 2007 Feb; 67(3):992-1000. PubMed ID: 17283131
[TBL] [Abstract][Full Text] [Related]
11. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein.
Bernardin F; Yang Y; Civin CI; Friedman AD
Cancer Biol Ther; 2002; 1(5):492-6. PubMed ID: 12496475
[TBL] [Abstract][Full Text] [Related]
12. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
Li L; Piloto O; Nguyen HB; Greenberg K; Takamiya K; Racke F; Huso D; Small D
Blood; 2008 Apr; 111(7):3849-58. PubMed ID: 18245664
[TBL] [Abstract][Full Text] [Related]
13. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
Elife; 2016 Nov; 5():. PubMed ID: 27879203
[TBL] [Abstract][Full Text] [Related]
14. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
[TBL] [Abstract][Full Text] [Related]
15. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
Thanasopoulou A; Tzankov A; Schwaller J
Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
[TBL] [Abstract][Full Text] [Related]
16. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
18. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.
Kummalue T; Lou J; Friedman AD
Mol Cell Biol; 2002 Dec; 22(23):8278-91. PubMed ID: 12417730
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
[TBL] [Abstract][Full Text] [Related]
20. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
Xue L; Pulikkan JA; Valk PJ; Castilla LH
Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]